While the prognostic significance of tumor angiogenesis remains a topic of intense interest and study, a California radiologist is waging a largely unnoticed campaign to promote neovascularity as a diagnostic marker for early stage breast cancer.
Gamagami's report represented the first major attempt at public discussion of angiogenesis' diagnostic potential in breast cancer. Gamagami and his colleagues will publish their first paper on the subject later this year in the Breast Journal. The radiologist has also begun work on a text that will review evidence collected over the past 15 years.
Authorities on tumor angiogenesis and breast cancer diagnosis say they are unaware of any other reports on the diagnostic potential of neovascularity.
By Gamagami's admission, the San Antonio presentation swayed few if any opinions. "If you don't have experience with something," he said, "you don't know what questions to ask."
On the basis of laboratory and clinical observations, the Van Nuys group believes that mammographically detectable breast cancer angiogenesis evolves in two stages: Preneoplastic cells secrete angiogenic factors that stimulate dormant blood vessels, which increase in number and size, and then a malignant lesion forms its own nutrient and drainage vessels. Over the course of time, contiguous calcifications that envelop the nutrient artery help distinguish the vessel from the drainage vein on mammography. Before It's Visible "Our work has demonstrated that these neovascular formations appear on mammography before the tumor is even visible," said Gamagami, although most physicians, he believes, overlook the formations or dismiss them as normal asymmetry. "What you don't know about, you don't look for."
Neovascularity may have played a role in the rise and fall of thermography's potential as a breast cancer diagnostic tool. The California group has found evidence that tumor angiogenesis causes mammographic "hot spots" in the affected breast even in the absence of recognized signs of developing cancer. The investigators have begun a clinical evaluation of the feasibility of performing thermography-guided biopsies.
"Thermography was eliminated from the diagnostic arsenal because the findings did not correlate with clinical findings, physical examination, and mammography," said Gamagami. "Everyone concluded that thermography had a high rate of false-positives. Now we know the reason for those false-positive findings: angiogenesis."
Outside the Van Nuys clinic, other cancer specialists remain skeptical about the diagnostic potential of angiogenesis. San Antonio radiologist Pam Otto, M.D., who saw the poster at the breast cancer symposium, questions the sensitivity and specificity of the approach.
"If you're talking about arterial circulation, that's microscopic and I think it will be very hard to see on mammography," said Otto, an assistant professor of radiology at the University of Texas Health Science Center in San Antonio.
Houston breast imaging specialist Carol Stelling, M.D., is unfamiliar with the work but questions its diagnostic value.
"To take out a [mammographically] busy breast and pick out a vascular pattern seems a little pie in the sky to me," said Stelling, head of breast imaging at the University of Texas M. D. Anderson Cancer Center in Houston. "I'm not saying that it's not possible, but how we position the breast and other factors can affect the view.
"Theoretically, we're looking at cellular changes and very small foci," Stelling continued. "For that to be reflected in a major change in an artery at a very early time frame seems unlikely. In theory, it doesn't seem like it would be necessary for the blood supply to change with the earliest, very small tumors."
Dr. Judah Folkman
Tumor angiogenesis authority Judah Folkman, M.D., of Harvard University, Boston, also is unaware of any reported findings involving the diagnostic potential of angiogenesis, but he would welcome such a development. "If they have indeed found something, that would be neat because I don't know of anyone else who has done that," said Folkman, the Julia Dyckman Andrus Professor of Pediatric Surgery. "We keep a running literature search of the whole field [of angiogenesis], and I don't recall having seen anything on diagnosis."
He adds that the group will likely face a questioning, skeptical oncology community until the investigators have a large, prospective patient series to validate their findings. "If they have only one abstract and no formal papers with statistical validation, I would suspect that the work will really be attacked," he said. "That doesn't mean it's not true, but people tend to be really skeptical because there is such a big potential for false-positive findings."
Gamagami and colleagues are no strangers to skepticism. "But before people decide this is right or wrong, I would just ask that they look at what we have done and talk to someone who has been working in this area for 15 years," said Gamagami.
"Eighty percent of the breast cancer patients who come to us already have a palpable mass," he explained. "Only 20% have a nonpalpable mass. If we could have an effect on the 80%, then we could have a real impact on breast cancer mortality." --Charles Bankhead
